Xeljanz 5 mg tablets

Reason for shortage

Anticipated shortage as Pfizer transitions manufacturing post-patent expiry. Rheumatoid arthritis patients should not stop JAK inhibitor therapy without guidance.

What to do

1. 1.
   Ensure you have adequate stock — Collect your current prescription promptly to build a small buffer before the anticipated shortage begins.
2. 2.
   Speak with your prescriber proactively — Discuss alternative options now, before the shortage occurs, so a plan is in place.
3. 3.
   Monitor TGA updates — Anticipated shortages may be resolved before they become active. Check the TGA MSI database regularly.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

• Olumiant (baricitinib) 4 mg — alternative JAK inhibitor
• Rinvoq (upadacitinib) — newer JAK inhibitor (check PBS eligibility)